Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors

Life Sciences

Volumn 79, Issue 8, 2006, Pages 791-800

  Pieretti, Stefano ^a   Dominici, Luigi ^a   Di Giannuario, Amalia ^a   Cesari, Nicoletta ^b   Dal Piaz, Vittorio ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Inflammation; Locomotor activity; Pain; PDE2; PDE3; PDE4; PDE5; Phosphodiesterase inhibitor; Pyridazinone derivatives

Indexed keywords

6 BENZYL 3 METHYL 4 PHENYLPYRAZOLO[3,4 D]PYRIDAZIN 7(6H) ONE; 9 (2 HYDROXY 3 NONYL)ADENINE; CILOSTAMIDE; ETHYL 6,7 DIHYDRO 6 ETHYL 3 METHYL 4 PHENYL 1H PYRROLO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; ETHYL 6,7 DIHYDRO 6 ETHYL 3 METHYL 7 OXO 4 PHENYLTHIENO[2,3 D]PYRIDAZINE 2 CARBOXYLATE; INDOMETACIN; PHOSPHODIESTERASE IV INHIBITOR; PYRIDAZINONE DERIVATIVE; ROLIPRAM; SILDENAFIL; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; HYPERALGESIA; INFLAMMATION; LOCOMOTION; MALE; NONHUMAN; PAIN THRESHOLD; PAW EDEMA;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; EDEMA; MALE; MICE; MOTOR ACTIVITY; PAIN MEASUREMENT; PAIN THRESHOLD; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; ROLIPRAM; ZYMOSAN;

ANIMALIA;

EID: 33745674029     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.02.026     Document Type: Article

References (45)

1. Abramowitz M., and Staging I.A. Handbook of Mathematical Functions with Formulas, Graphs, and Mathematical Tables, 9th printing (1972), Dover, New York 886
2. Ambriz-Tututi M., Velázquez-Zamora D.A., Urquiza-Marín H., and Granados-Soto V. Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test. European Journal of Pharmacology 512 (2005) 121-127
3. Asomoza-Espinosa R., Alonso-Lopez R., Mixcoatl-Zecuatl T., Aguirre-Bañuelos P., Torres-Lopez J.E., and Granados-Soto V. Sildenafil increases diclofenac antinociception in the formalin test. European Journal of Pharmacology 418 (2001) 195-200
4. Bucci M., Roviezzo F., Cicala C., Sessa W.C., and Cirino G. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. British Journal of Pharmacology 131 (2000) 13-16
5. Calhoun W., Chang J., and Carlson R.P. Effect of selected anti-inflammatory agents and other drugs on zymosan, arachidonic acid, PAF and carrageenan induced paw edema in the mouse. Agents and Actions 21 (1987) 306-309
6. Cunha F.Q., Teixeira M.M., and Ferreira S.H. Pharmacological modulation of secondary mediator systems-cyclic AMP and cyclic GMP-on inflammatory hyperalgesia. British Journal of Pharmacology 127 (1999) 671-678
7. Dal Piaz V., Giovannoni M.P., Castellana C., Palacios J.M., Beleta J., Domenech T., and Segarra V. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. Journal of Medicinal Chemistry 40 (1997) 1417-1421
8. Davis C.W. Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochimica et Biophysica Acta 797 (1984) 354-362
9. Doherty A.M. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Current Opinion in Chemical Biology 3 (1999) 466-473
10. Duarte I.D., and Ferreira S.H. L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. Mediators of Inflammation 9 (2000) 25-30
11. Dyke H.J., and Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opinion on Investigational Drugs 11 (2002) 1-13
12. Feixas J., Giovannoni M.P., Vergelli C., Gavaldà A., Cesari N., Graziano A., and Dal Piaz V. New pyrazolo [1′, 5′:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors. Bioorganic and Medicinal Chemistry Letters 15 (2005) 2381-2384
13. Fleischhacker W.W., Hinterhuber H., Bauer H., Pflug B., Berner P., Simhandl C., Wolf R., Gerlach W., Jaklitsch H., Sastre-y-Hernandez M., et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26 (1992) 59-64
14. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Progress in Nucleic Acid Research and Molecular Biology 65 (2001) 1-52
15. Francischi J.N., Yokoro C.M., Poole S., Tafuri W.L., Cunha F.Q., and Teixeira M.M. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. European Journal of Pharmacology 399 (2000) 243-249
16. Hoheisel U., Unger T., and Mense S. The possible role of the NO-cGMP pathway in nociception: different spinal and supraspinal action of enzyme blockers on rat dorsal horn neurones. Pain 117 (2005) 358-367
17. Huang Z., Ducharme Y., Macdonald D., and Robichaud A. The next generation of PDE4 inhibitors. Current Opinion in Chemical Biology 5 (2001) 432-438
18. Hunter J.A., and Blyth T.H. A risk-benefit assessment of intra-articular corticosteroids in rheumatic disorders. Drug Safety 21 (1999) 353-365
19. Jacob C., Martin-Chouly C., and Lagente V. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes. Therapie 57 (2002) 163-168
20. Jain K.N., Patil C.S., Singh A., and Kulkarni S.K. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Research 909 (2001) 170-178
21. Jeon Y.H., Heo Y.-S., Kim C.M., Hyun Y.-L., Lee T.G., Ro S., and Cho J.M. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cellular and Molecular Life Sciences 62 (2005) 1198-1220
22. Kress M., Rodl J., and Reeh P.W. Stable analogues of cyclic AMP but not cyclic GMP sensitize unmyelinated primary afferents in rat skin to heat stimulation but not to inflammatory mediators, in vitro. Neuroscience 74 (1996) 609-617
23. Laughlin T.M., Tram K.V., Wilcox G.L., and Birnbaum A.K. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. Journal of Pharmacology and Experimental Therapeutics 302 (2002) 1168-1175
24. Laux G., Becker T., Kuhne G., Lesch K.P., Riederer P., and Beckmann H. Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed in patients controlled by determination of plasma level. Pharmacopsychiatry 21 (1988) 378-379
25. Litchfield J.T., and Wilcoxon F.A. A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96 (1949) 99-113
26. Loggi G., Laviola G., Alleva E., and Chiarotti F. Morphine effects on mouse locomotor/exploratory activity: test dependency, test reliability, uni- and multi-variate analyses. Pharmacology Biochemistry and Behaviour 38 (1991) 817-822
27. Machelska H., Przewlocki R., Radomski M.W., and Przewlocka B. Differential effects of intrathecally and intracerebroventricularly administered nitric oxide donators on noxious mechanical and thermal stimulation. Polish Journal of Pharmacology 50 (1998) 407-415
28. Meller S.T., Cummings C.P., Traub R.J., and Gebhart G.F. The role of nitric oxide in the development and maintenance of the hyperalgesia produced by intraplantar injection of carrageenan in the rat. Neuroscience 60 (1994) 347-367
29. Mixcoatl-Zecuatl T., Aguirre-Bañuelos P., and Granados-Soto V. Sildenafil produces antinociception and increases morphine antinociception in the formalin test. European Journal of Pharmacology 400 (2000) 81-87
30. Mizokawa T., Kimura K., Ikoma Y., Hara K., Oshino N., Yamamoto T., and Ueki S. The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats. Japanese Journal of Pharmacology 48 (1988) 357-364
31. Pieretti S., Di Giannuario A., Capasso A., Sorrentino L., and Loizzo A. Effects induced by cysteamine on chemically-induced nociception in mice. Life Sciences 54 (1994) 1091-1099
32. Robichaud A., Tattersall Fd., Choudhury I., and Rodger I.W. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38 (1999) 289-297
33. Sakurada C., Sugiyama A., Nakayama M., Yonezawa A., Sakurada S., TanNo K., Kisara K., and Sacurada T. Antinociceptive effect of spinally injected L-NAME on the acute nociceptive response induced by low concentrations of formalin. Neurochemistry International 38 (2001) 417-423
34. Silvestre J.S., Fernandez A.G., and Palacios J.M. Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats. Pharmacology, Biochemistry and Behaviour 64 (1999) 1-5
35. Sluka K.A. Activation of the cAMP transduction cascade contributes to the mechanical hyperalgesia and allodynia induced by intradermal injection of capsaicin. British Journal of Pharmacology 122 (1997) 1165-1173
36. Souness J.E., Aldous D., and Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47 (2000) 127-162
37. Sufka K.J., Watson G.S., Nothdurft R.E., and Mogil J.S. Scoring the mouse formalin test: validation study. European Journal of Pain 2 (1998) 351-358
38. Taiwo Y.O., and Levine J.D. Kappa- and delta-opioids block sympathetically dependent hyperalgesia. Journal of Neuroscience 11 (1991) 928-932
39. Teixeira M.M., Gristwood R.W., Cooper N., and Hellewell P.G. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?. Trends in Pharmacological Sciences 18 (1997) 164-171
40. Torres-López J.E., and Granados-Soto V. Peripheral participation of the phosphodiesterase 3 on formalin-evoked nociception. European Journal of Pharmacology 519 (2005) 75-79
41. Wachtel H. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77 (1982) 309-316
42. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22 (1983) 267-272
43. Wachtel H., Paschelke G., and Erhard C. Neuroleptic-like activity of rolipram, a novel pyrrolidone derivative, in mice. Naunyn-Schmiedeberg's Archives of Pharmacology 308 (1979) R44 (Suppl.)
44. Wachtel H., Loschmann P.-A., Schneider H.H., and Retting K.-J. Effects of forskolin on spontaneous behavior, rectal temperature and brain cAMP levels of rats: interaction with rolipram. Neuroscience Letters 76 (1987) 191-196
45. Zeller E. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17 (1984) 188-190